Cigna exec Jones trades stock, gets new awards

Cigna Group executive Nicole S. Jones reported a mix of stock transactions.

Rhea-AI Filing Summary

Cigna Group executive Nicole S. Jones reported a mix of stock transactions. She sold 2,307 shares of common stock at $288.91 per share in an open-market sale executed under a Rule 10b5-1 trading plan adopted on May 8, 2025.

Earlier on February 27, 2026, she received 8,066 employee stock options and 9,367 shares of common stock through equity awards and performance share settlement at no cash cost. On the same date, 2,738 shares were withheld to cover tax obligations tied to those awards.

After these transactions, she directly held 32,647 shares of Cigna common stock and 8,066 stock options, and indirectly held 1,434.7897 shares through participation in The Cigna Group’s 401(k) Plan.

Insider Trade Summary

Net Seller: 2,307 shares

Net Sell 7 txns

Insider Jones Nicole S

Role See Remarks

Sold 2,307 shs ($667K)

Type	Security	Shares	Price	Value
Sale	Common Stock, $.01 Par Value	2,307	$288.91	$667K
Grant/Award	Employee Stock Option (Right to Buy)	8,066	$0.00	$0.00
Grant/Award	Common Stock, $.01 Par Value	4,133	$0.00	$0.00
Grant/Award	Common Stock, $.01 Par Value	5,234	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock, $.01 Par Value	1,826	$287.55	$525K
Exercise Price or Tax Liability	Common Stock, $.01 Par Value	912	$287.55	$262K
holding	Common Stock, $.01 Par Value	--	--	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 8,066 contracts (Direct); Common Stock, $.01 Par Value — 32,647 shares (Direct); Common Stock, $.01 Par Value — 1,434.7897 shares (Indirect, By 401(k))

Footnotes (7)

1. F1. The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2023-2025 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals.
2. F2. These restricted shares vest in three equal annual installments beginning March 1, 2027.
3. F3. Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares.
4. F4. Represents shares withheld to satisfy tax obligations upon vesting of restricted shares.
5. F5. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2025.
6. F6. Represents shares acquired through ongoing participation in The Cigna Group's 401(k) Plan.
7. F7. This option vests in three equal annual installments beginning March 1, 2027.

FAQ

What stock transactions did Cigna (CI) executive Nicole S. Jones report?

Nicole S. Jones reported an open-market sale of 2,307 Cigna shares and multiple equity awards. She also had shares withheld for tax obligations and reported indirect ownership through The Cigna Group’s 401(k) Plan, reflecting routine executive compensation and planning activity.

How many Cigna (CI) shares did Nicole S. Jones sell and at what price?

She sold 2,307 shares of Cigna common stock at $288.91 per share. The transaction was an open-market sale executed under a pre-established Rule 10b5-1 trading plan, indicating the sale followed a preset schedule rather than a discretionary decision at that moment.

What new equity awards did Nicole S. Jones receive from Cigna (CI)?

She received 8,066 employee stock options and 9,367 shares of common stock through grants and settlement of strategic performance shares. The options and certain restricted shares vest in three equal annual installments beginning March 1, 2027, linking potential value to multi-year company performance and retention.

How many Cigna (CI) shares were withheld to cover Nicole S. Jones’s taxes?

A total of 2,738 Cigna common shares were withheld to satisfy tax obligations. Footnotes state 1,826 shares related to strategic performance share settlement and 912 shares related to restricted share vesting, reflecting non-cash tax payments tied to equity compensation events.

What is Nicole S. Jones’s Cigna (CI) share ownership after these transactions?

Following the reported transactions, she directly owned 32,647 Cigna common shares and 8,066 employee stock options. She also indirectly held 1,434.7897 shares through The Cigna Group’s 401(k) Plan, demonstrating both direct and retirement-plan-based exposure to the company’s stock.

Was Nicole S. Jones’s Cigna (CI) stock sale under a Rule 10b5-1 plan?

Yes. A footnote specifies the 2,307-share sale was executed under a Rule 10b5-1 trading plan adopted on May 8, 2025. Such plans pre-schedule trades, aiming to separate normal portfolio diversification from opportunistic trading based on non-public information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 07:18 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jones Nicole S

(Last) (First) (Middle)

900 COTTAGE GROVE ROAD

(Street)

BLOOMFIELD CT 06002

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cigna Group [ CI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $.01 Par Value	02/27/2026		A		4,133(1)	A	$0	32,458	D
Common Stock, $.01 Par Value	02/27/2026		A		5,234(2)	A	$0	37,692	D
Common Stock, $.01 Par Value	02/27/2026		F		1,826(3)	D	$287.55	35,866	D
Common Stock, $.01 Par Value	02/27/2026		F		912(4)	D	$287.55	34,954	D
Common Stock, $.01 Par Value	03/02/2026		S(5)		2,307	D	$288.91	32,647	D
Common Stock, $.01 Par Value								1,434.7897(6)	I	By 401(k)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$287.5475	02/27/2026		A		8,066		03/01/2027(7)	02/27/2036	Common Stock, $.01 Par Value	8,066	$0	8,066	D

Explanation of Responses:

1. The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2023-2025 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals.

2. These restricted shares vest in three equal annual installments beginning March 1, 2027.

3. Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares.

4. Represents shares withheld to satisfy tax obligations upon vesting of restricted shares.

5. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2025.

6. Represents shares acquired through ongoing participation in The Cigna Group's 401(k) Plan.

7. This option vests in three equal annual installments beginning March 1, 2027.

Remarks:

	Tyler Gratton, attorney-in-fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.